The addition of LPS as a TLR4 agonist increased the differentiation into CD27++CD38++ ASCs in both the AChR-MG and MuSK-MG samples with a correlation to increase IgG production, whereas the LPS in controls reduced the effect. The gene discussed is CD27; the disease is myasthenia gravis.